keyword
https://read.qxmd.com/read/38532123/correction-to-identification-of-a-novel-fusion-gene-rara-ankrd34c-in-acute-promyelocytic-leukemia
#1
Yue Chen, Mengge Pan, Lanxin Chen, Miaoxin Peng, Zhenyu Liu, Yiran Fang, Ying Du, Yonggong Yang, Peipei Xu
No abstract text is available yet for this article.
March 27, 2024: Annals of Hematology
https://read.qxmd.com/read/38532122/the-influence-of-hospital-volume-and-physician-volume-on-early-mortality-in-acute-promyelocytic-leukemia-patients
#2
JOURNAL ARTICLE
Chia-Ying Wu, Chiu-Mei Yeh, Chun-Kuang Tsai, Chia-Jen Liu
Acute promyelocytic leukemia (APL) is a highly curable hematologic malignancy in the era of all-trans retinoic acid (ATRA) combination treatment. However, only a modest change in early mortality rate has been observed despite the wide availability of ATRA. In addition to the clinical characteristics of APL patients, studies on the hospital volume-outcome relationship and the physician volume-outcome relationship remained limited. We aim to evaluate the association between hospital and physician volume and the early mortality rate among APL patients...
March 26, 2024: Annals of Hematology
https://read.qxmd.com/read/38524920/survival-of-adult-aml-patients-treated-with-chemotherapy-in-the-u-s-population-by-age-race-and-ethnicity-sex-calendar-year-period-and-aml-subgroup-2001-2019
#3
JOURNAL ARTICLE
Martha S Linet, Rochelle E Curtis, Sara J Schonfeld, Jacqueline B Vo, Lindsay M Morton, Graça M Dores
BACKGROUND: Population-based survival studies of adult acute myeloid leukemia (AML) have not simultaneously evaluated age at diagnosis, race and ethnicity, sex, calendar period or AML subtypes/subgroups among chemotherapy-treated patients. METHODS: For 28,473 chemotherapy-treated AML patients diagnosed at ages ≥20 years in population-based cancer registry areas of the Surveillance, Epidemiology, and End Results Program (2001-2018, followed through 2019), we evaluated 1-month through 5-year relative survival (RS) and 95% confidence intervals (95% CI) using the actuarial method in the SEER∗Stat Survival Session and overall survival (OS) using multivariable Cox regression to estimate proportional hazard ratios (HR) and 95% CI...
May 2024: EClinicalMedicine
https://read.qxmd.com/read/38516455/fatal-differentiation-syndrome-complicating-acute-promyelocytic-leukemia-treatment-a-case-report
#4
Umair Khizer, Bhavana Annam, Akasha Akhtar, Jasninder S Dhaliwal, Chieh Yang
We report the case of a 42-year-old female diagnosed with acute promyelocytic leukemia (APL), who developed differentiation syndrome (DS) on day 14 during induction therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) with sudden-onset dyspnea, abdominal pain, tachycardia, and fever. Her laboratory findings were remarkable for acute kidney injury (AKI), worsening leukocytosis, thrombocytopenia, and lactic acidosis. She was also found to have flash pulmonary edema and a pericardial effusion...
February 2024: Curēus
https://read.qxmd.com/read/38507743/the-cdk4-6-inhibitor-palbociclib-synergizes-with-atra-to-induce-differentiation-in-aml
#5
JOURNAL ARTICLE
Linhui Hu, Qian Li, Jiyu Wang, Huiping Wang, Xiyang Ren, Keke Huang, Yangyang Wang, Xue Liang, Lianfang Pu, Shudao Xiong, Zhimin Zhai
Differentiation therapy based on ATRA almost cured acute promyelocytic leukemia (APL). However, it is disappointing that ATRA is not effective against other acute myeloid leukemia (AML) subtypes. Developing new and effective anti-AML therapies that promote leukemia differentiation is necessary. The CDK4/6-cyclin D pathway is a key initiator of the G1/S phase transition, which determines cell fate. Herein, we investigated whether the CDK4/6 inhibitor palbociclib would synergize with ATRA to promote leukemia differentiation in vitro and in vivo...
March 20, 2024: Molecular Cancer Therapeutics
https://read.qxmd.com/read/38507294/superiority-of-anthracycline-free-treatment-in-standard-risk-acute-promyelocytic-leukemia-a-systematic-review-and-comparative-epidemiological-analysis
#6
REVIEW
Kane Langdon, Stevie Cosentino, Olivia Wawryk
BACKGROUND: Recent advances in the treatment of acute promyelocytic leukemia (APML) have seen unprecedented improvements in patient outcomes. However, such rapid growth in understanding often leads to uncertainty regarding superiority among candidate treatment regimens, especially when further scrutinized from an epidemiological perspective. AIMS: The aim of this systematic review with epidemiological analysis was to identify and compare commonly utilized protocols for standard-risk APML with a particular focus on complete remission (CR), overall/disease-free survival (DFS), and reported adverse events...
March 2024: Cancer reports
https://read.qxmd.com/read/38503533/-a-case-of-recurrent-acute-promyelocytic-leukemia-with-p-r394g-resistance
#7
JOURNAL ARTICLE
Y Shi, J J Yao, Y H Yao, Z B Liu, F Gao, X Y Li, S Q Feng
No abstract text is available yet for this article.
December 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38503502/acute-promyelocytic-leukemia-retinoic-acid-and-arsenic-a-tale-of-dualities
#8
JOURNAL ARTICLE
Domitille Rérolle, Hsin-Chieh Wu, Hugues de Thé
Acute promyelocytic leukemia (APL) is driven by the promyelocytic leukemia (PML)/retinoic acid receptor α (RARA) fusion oncoprotein. Over the years, it has emerged as a model system to understand how this simple (and sometimes sole) genetic alteration can transform hematopoietic progenitors through the acquisition of dominant-negative properties toward both transcriptional control by nuclear receptors and PML-mediated senescence. The fortuitous identification of two drugs, arsenic trioxide (ATO) and all- trans -retinoic acid (ATRA), that respectively bind PML and RARA to initiate PML/RARA degradation, has allowed an unprecedented dissection of the cellular and molecular mechanisms involved in patients' cure by the ATO/ATRA combination...
March 19, 2024: Cold Spring Harbor Perspectives in Medicine
https://read.qxmd.com/read/38495096/research-progress-on-arsenic-arsenic-containing-medicinal-materials-and-arsenic-containing-preparations-clinical-application-pharmacological-effects-and-toxicity
#9
REVIEW
Yichu Yang, Yiye Li, Ran Li, Zhang Wang
Introduction: The toxicity of arsenic is widely recognized globally, mainly harming human health by polluting water, soil, and food. However, its formulations can also be used for the clinical treatment of diseases such as leukemia and tumors. Arsenic has been used as a drug in China for over 2,400 years, with examples such as the arsenic-containing drug realgar mentioned in Shennong's Herbal Classic. We have reviewed references on arsenic over the past thirty years and found that research has mainly focused on clinical, pharmacological, and toxicological aspects...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38494827/an-isolated-sacral-promyelocytic-sarcoma-in-a-child-a-rare-case-report-with-emphasis-on-cytomorphology
#10
JOURNAL ARTICLE
Jeongeun Do, Talal Arshad, Juanita Emily Ferreira, Leonard Nsoyori Yenwongfai, Hafsa Nebbache, Derek Blake Allison, Dava West Piecoro, Melissa Vandyke Kesler
Myeloid sarcoma (MS) is an uncommon localized extramedullary tumor composed of immature myeloid precursor cells that can affect any organ. Promyelocytic sarcoma (PS), an extremely rare subtype of MS, is characterized by immature myeloid cells with features of acute promyelocytic leukemia (APL). We describe a case of pediatric PS that presented as a solitary sacral mass without any evidence of systemic or bone marrow involvement. The cytopathologic evaluation using touch imprint demonstrated numerous blasts with bilobed nuclei, cytoplasmic hyper-granularity, and aggregates of Auer rods, which are typical cytomorphologic features of APL...
March 17, 2024: Diagnostic Cytopathology
https://read.qxmd.com/read/38494811/a-case-of-relapsed-refractory-cd56-positive-acute-promyelocytic-leukemia-in-which-complete-molecular-remission-was-achieved-following-combination-therapy-with-venetoclax-and-azacitidine
#11
JOURNAL ARTICLE
Yasunobu Sekiguchi, Hiroki Tsutsumi, Ayumi Gomyo, Masahisa Kudo, Nobuo Maseki, Yoshie Iizaki, Machiko Kawamura, Kazuhiko Kobayashi, Hideaki Nitta, Masaaki Noguchi, Satoshi Wakita, Hiroki Yamaguchi, Hirofumi Kobayashi
An 84-year-old woman was diagnosed as having acute promyelocytic leukemia(APL)in July Year X-3. The test for promyelocytic leukemia- retinoic acid receptor alpha(PML-RARA)mRNA was positive, while that for CD56 was negative. Since her white blood cell( WBC) count was <3,000/μL, with a count of APL cells of <1,000/μL, she was started on monotherapy with all-trans retinoic acid(ATRA). In September Year X-3, complete hematological remission(CHR)was confirmed. she refused to provide consent for receiving consolidation therapy...
March 2024: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38471725/mitral-valve-dysfunction-in-a-woman-with-newly-diagnosed-acute-promyelocytic-leukemia
#12
JOURNAL ARTICLE
Matthew J Bierowski, Eric D Warner, Chelsea D Edirisuriya
No abstract text is available yet for this article.
March 12, 2024: Heart
https://read.qxmd.com/read/38467608/usp22-regulates-apl-differentiation-via-pml-rar%C3%AE-stabilization-and-ifn-repression
#13
JOURNAL ARTICLE
Lisa Kowald, Jens Roedig, Rebekka Karlowitz, Kristina Wagner, Sonja Smith, Thomas Juretschke, Petra Beli, Stefan Müller, Sjoerd J L van Wijk
Ubiquitin-specific peptidase 22 (USP22) is a deubiquitinating enzyme (DUB) that underlies tumorigenicity, proliferation, cell death and differentiation through deubiquitination of histone and non-histone targets. Ubiquitination determines stability, localization and functions of cell fate proteins and controls cell-protective signaling pathways to surveil cell cycle progression. In a variety of carcinomas, lymphomas and leukemias, ubiquitination regulates the tumor-suppressive functions of the promyelocytic leukemia protein (PML), but PML-specific DUBs, DUB-controlled PML ubiquitin sites and the functional consequences of PML (de)ubiquitination remain unclear...
March 11, 2024: Cell Death Discovery
https://read.qxmd.com/read/38467145/thrombosis-in-acute-promyelocytic-leukemia-the-current-understanding
#14
JOURNAL ARTICLE
Nikica Sabljic, Mirjana Mitrovic, Nikola Pantic, Jecko Thachil
Despite enormous improvement in the management of patients with acute promyelocytic leukemia (APL), the distinctive coagulopathy observed at presentation in affected patients is often life-threatening. While hemorrhagic manifestations are well known and described in this setting, APL-related thromboses are underappreciated. Data regarding this complication are scarce showing variable incidence. Furthermore, risk factors for thrombosis are inconsistent and unreliable; so, differentiation of increased risk of hemorrhage from an increased thrombotic risk is quite difficult in the absence of adequate predictive scores...
March 11, 2024: Hämostaseologie
https://read.qxmd.com/read/38450185/clinical-analysis-of-82-cases-of-acute-promyelocytic-leukemia-with-pml-rar%C3%AE-short-isoform-in-children-and-adults
#15
JOURNAL ARTICLE
Qiaolin Huang, Yicheng Zhang, Miao Zheng
BACKGROUND: Acute promyelocytic leukemia (APL) with PML/RARα fusion gene is a distinct variant of acute myeloid leukemia. According to the different break sites of the PML gene, there are three transcripts: Long (bcr1), Variant (bcr2) and Short (bcr3). METHODS: We retrospectively analyzed 82 APL cases with PML-RARα short isoform. RESULTS: A total of 384 patients with APL were seen, of which 85(22.14%) had PML/RARα short isoform (bcr3) and 82 met the inclusion criteria...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38434265/case-report-of-pediatric-ttmv-related-acute-promyelocytic-leukemia-with-central-nervous-system-infiltration-and-rapid-accumulation-of-rara-lbd-mutations
#16
Linya Wang, Jiaqi Chen, Bei Hou, Ying Wu, Jun Yang, Xiaosu Zhou, Qihui Chen, Xue Chen, Yang Zhang, Fang Wang, Jiancheng Fang, Panxiang Cao, Mingyue Liu, Yanan Li, Pan Zhang, Yan Liu, Ruidong Zhang, Hongxing Liu, Huyong Zheng
TTMV::RARA is a recently reported fusion gene associated with acute promyelocytic leukemia (APL), caused by the integration of torque teno mini virus (TTMV) genomic fragments into the second intron of the RARA gene. Currently, there have been only six documented cases, with clinical presentations showing significant variability. Although initial responses to all-trans retinoic acid (ATRA) treatment may be observed in patients with TTMV :: RARA -APL, the overall prognosis remains unfavorable among infrequent reported cases...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38431521/outcome-of-patients-with-relapsed-acute-promyelocytic-leukemia
#17
JOURNAL ARTICLE
Koji Sasaki, Farhad Ravandi, Tapan Kadia, Courtney D DiNardo, Musa Yilmaz, Nicholas Short, Elias Jabbour, Keyur P Patel, Sanam Loghavi, Sherry Pierce, Gautam Borthakur, Hagop Kantarjian
BACKGROUND: The outcome of patients with acute promyelocytic leukemia (APL) has improved significantly since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as APL therapies. The optimal therapy for APL relapse is believed to require autologous or allogeneic stem cell transplantation (SCT) based on historical experience. STUDY AIMS: To evaluate the outcome of patients with relapsed APL before and after the era of ATRA-ATO. PATIENTS AND METHODS: We reviewed 61 patients with relapsed APL treated from November 1991 to June 2023; 31 patients (51%) received modern therapy with the combination of ATRA and ATO with and without idarubicin and gemtuzumab ozogamicin (GO)...
February 3, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38424137/nucleic-acid-therapeutics-as-differentiation-agents-for-myeloid-leukemias
#18
REVIEW
Olivia Kovecses, François E Mercier, Maureen McKeague
Differentiation therapy has proven to be a success story for patients with acute promyelocytic leukemia. However, the remaining subtypes of acute myeloid leukemia (AML) are treated with cytotoxic chemotherapies that have limited efficacy and a high likelihood of resistance. As differentiation arrest is a hallmark of AML, there is increased interest in developing differentiation-inducing agents to enhance disease-free survival. Here, we provide a comprehensive review of current reports and future avenues of nucleic acid therapeutics for AML, focusing on the use of targeted nucleic acid drugs to promote differentiation...
February 29, 2024: Leukemia
https://read.qxmd.com/read/38421051/pituitary-apoplexy-in-acute-promyelocytic-leukemia
#19
Eitan Mirvis, Shwetha Sairam, Erika Vainieri, Francesca Tona, Catherine Hockings, Renuka Palanicawandar, Elisabet Nadal-Melsio
No abstract text is available yet for this article.
February 29, 2024: American Journal of Hematology
https://read.qxmd.com/read/38411156/pml-nuclear-bodies-the-cancer-connection-and-beyond
#20
REVIEW
Majdouline Abou-Ghali, Valérie Lallemand-Breitenbach
Promyelocytic leukemia (PML) nuclear bodies, membrane-less organelles in the nucleus, play a crucial role in cellular homeostasis. These dynamic structures result from the assembly of scaffolding PML proteins and various partners. Recent crystal structure analyses revealed essential self-interacting domains, while liquid-liquid phase separation contributes to their formation. PML bodies orchestrate post-translational modifications, particularly stress-induced SUMOylation, impacting target protein functions...
December 2024: Nucleus
keyword
keyword
94790
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.